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Abstract
Background: High-resolution magic angle spinning (HRMAS) NMR spectroscopy allows detailed metabolic analysis
of whole biopsy samples for investigating tumour biology and tumour classification. Accurate biochemical
assignment of small molecule metabolites that are “NMR visible” will improve our interpretation of HRMAS data
and the translation of NMR tumour biomarkers to in-vivo studies.
Results: 1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with
8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour
(astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas). Differences
in concentration of 20 of these metabolites were statistically significant between these brain tumour types. During
the course of an extended 2D data acquisition the HRMAS technique itself affects sample analysis: glycine,
glutathione and glycerophosphocholine all showed small concentration changes; analysis of the sample after
HRMAS indicated structural damage that may affect subsequent histopathological analysis.
Conclusions: A number of small molecule metabolites have been identified as potential biomarkers of tumour
type that may enable development of more selective in-vivo 1H NMR acquisition methods for diagnosis and
prognosis of brain tumours.
Background
Nuclear Magnetic Resonance (NMR) Spectroscopy has
been used to assign and quantify the small molecule
metabolites in brain tumours. In-vivo Magnetic Reso-
nance Spectroscopy (MRS, reviewed in [1]) allows for
the assignment and quantification of small molecule
metabolites in intracranial tumours. The various
intracranial tumour types have different metabolic
profiles in 1H MR spectra and pattern recognition of
these profiles has been used to develop a decision-
support system that can assist in the radiological
diagnosis and grading of brain tumours [2]. The main
potential of MRS in radiological diagnosis lies in aid-
ing binary decisions between tumour types that can
be challenging for a radiological diagnosis using con-
ventional MRI [3]; for example, between lymphoma
and glioblastoma (GBM) or metastasis and GBM.
While a “black-box” pattern recognition approach
may prove useful for such diagnostic decisions it is
also important to have a biological understanding of
the spectra, particularly in the assignment and quanti-
fication of individual metabolites, as this may allow
refinement of the acquisition protocol towards
improving the accuracy of tumour classification. The
low spectral resolution of the current in-vivo MRS in
clinical practice produces spectra dominated by the
larger peaks (e.g. Creatines, Cholines, myo-Inositol
(m-Ins), lipids and macromolecules) that mask the
contribution of smaller resonances -e.g. taurine (Tau)
and glycine (Gly)- to the overall profile. As spectral
resolution improves, due to higher field strength MRI
systems becoming more readily available (e.g. 3 T for
routine clinical use and up to 9.4 T for clinical
research), in-vivo MRS will be able to detect increas-
ing numbers of metabolites. The quantification of
these metabolites may provide useful biomarkers
for diagnosis and prognosis of brain tumours. Ex-vivo
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1H- High-Resolution Magic Angle Spinning (HRMAS)
NMR provides quantitative information on these
small molecule metabolites in unprocessed brain tis-
sue [4], but at a much higher spectral resolution than
is currently available in clinical MRS studies, provid-
ing an indication of all the NMR-visible metabolites
that are potentially observable in vivo. Additionally
the tissue sample is available for further analysis (e.g.
histopathology or genetic) after the experiment.
HRMAS has been previously used in several studies
of brain tumour tissue [5-11] and the concentrations
of the main tumour metabolites that are measured
show good agreement between in-vivo MRS and
ex-vivo HRMAS for several tumour types [10,12-14].
Other pathologies have also been investigated using
quantitative ex-vivo HRMAS [15,16]. This paper pro-
vides assignments for metabolites that are observable
for the most common histopathological types of adult
intracranial tumour (gliomas of grade II to IV, menin-
giomas, metastases and also lymphomas) and reports
their quantitation. Metastatses are the most common
intracranial tumours [17] while GBM, other gliomas,
meningiomas and lymphomas account for 17%, 13%,
30% and 3% respectively of diagnoses of primary CNS
tumours in the USA [18]. The assignment and quanti-
fication presented here provides sets of metabolites
that may prove significant in future in-vivo MRS stu-
dies of various adult-intracranial tumours. This paper
extends previous HRMAS studies of intracranial
tumours, which have for example, identified the com-
mon metabolites in normal brain [19], in some indivi-
dual adult [7,9] and pediatric [13] brain tumours. We
now extend this work to include more brain tumour
types (lymphoma and metastases), with additional
small molecule metabolites assigned and quantified.
Novel assignments of small molecule metabolites in
particular brain tumour types have also been made
that may provide biomarkers to aid specific tumour
classifications. This paper also extends quantification
of brain tumour metabolites in gliomas [8] to a range
of adult intracranial tumours. An evaluation of
changes in metabolite concentration that may occur
as a result of the experimental conditions and the
effects of tissue damage on histopathological re-exam-
ination post-HRMAS are also included in this work.
Concentration measurements were made using
LCModel [20] software that fits the spectral data with
a linear combination of spectra of individual metabo-
lites. The basis set of these metabolite spectra are
modelled using computer simulation [21] based on
the chemical shift assignment determined in this cur-
rent work.
Results and Discussion
Peak assignments, metabolite concentrations and
artefacts
Assignment of NMR visible small molecule metabolites
Analysis of a subset of 15 samples of five different histo-
pathological types of brain tumour allowed for the
assignment of 29 small molecule metabolites. These
metabolites are acetate (Ace), alanine (Ala), ascorbate
(Asc), aspartate (Asp), betaine (Bet), choline (Cho), crea-
tine (Cr), glucose (Glc), glutamate (Glu), glutamine
(Gln), glutathione (GSH), glycerophosphocholine (GPC),
glycerophosphoethanolamine (GPE), glycine, histidine
(His), hypotaurine (h-Tau), isoleucine (Ile), lactate (Lac),
leucine (Leu), myo-inositol, N-acetyl-aspartate (NAA),
phosphocholine (PCh), phosphoethanolamine (PE),
scyllo-inositol (s-Ins), succinate (Suc), taurine, threonine
(Thr) and valine (Val). CPMG (Carr-Purcell-Meiboom-
Gill) spectra, with a total echo time of 50 ms were
collected to measure metabolites chemical shift. Macro-
molecules are larger than the small molecule metabo-
lites and as a result they have significantly quicker T2
relaxation. The CPMG sequence acts as a T2 filter,
greatly reducing the signal of these faster relaxing
macromolecules compared to the smaller metabolites.
There are smaller differences in T2 relaxation between
the metabolites leading to variations in their peak
heights, widths and resolution from neighbouring peaks.
These variations make the quantification from CPMG
spectra unreliable and so they are only used for assign-
ment. Initial assignments of previously reported metabo-
lites were made with reference to the literature, as listed
in Table 1, with the main sources of reference being
Govindaraju et al. [19] and Martínez-Bisbal et al. [7].
Assignments for most metabolites (Ace, Ala, Asc, Asp,
Cho, Cr, Glc, Glu, Gln, GSH, GPC, Gly, Ile, Lac, Leu,
Lys, m-Ins, NAA, PCh, s-Ins, Suc, Tau, Thr, Val) are
well established in the literature of brain tumours
[6,22-25] other tumours [26] and tumour cell culture
[27] with in-vitro and ex-vivo high resolution NMR.
However, the primary references of Govindaraju et al
[19] and Martínez-Bisbal et al. [7] are peak assignments
from solution NMR of common brain metabolites and
of resonances specific to GBM respectively. Further,
novel assignments have been made for metabolites pre-
viously unreported in some of these tumour types; for
example, His and Bet have been observed and assigned
in some glioma spectra in this study. GPE assignments
were made using TOCSY (Total Correlation Spectro-
scopy) spectra as their peaks overlap with bigger reso-
nances in one dimensional spectra. GPE has a clearly
defined cross peak in some spectra (see Figure 1) that
was assigned with reference to its presence in HRMAS
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spectra of prostate [28] and cultured melanoma cell
lines [29]. H-Tau has been reported in meningiomas
[9,24] and in astroglial [30] and glioma cell lines [27,31]
and we have now observed this ex vivo in gliomas and
lymphomas as well as meningiomas. Asc is unreported
to date in NMR spectra of brain tumours and here was
assigned with reference to the Human Metabolomics
Project database [32,33], the Biological Magnetic Reso-
nance Bank small molecule database [34] and a 1D
pulse acquire spectrum acquired from a 50 mM Asc
solution with 10% D2O and 10 mM sodium formate as
a chemical shift reference.
Other, relatively small, resonances still remain unas-
signed. A singlet was observed at 3.69 ppm, present in
seven spectra of varying histopathological type, and a
multiplet at 2.2 ppm was observed in 2 astrocytoma II
spectra. A doublet at 1.16 ppm was observed in five
meningioma and 2 GBM’s CPMG spectra that is tenta-
tively assigned as the methyl group of 3-hydroxybutyrate
with reference to previous studies [24,31,35]. However,
although cross peaks are expected in the TOCSY at 2.4
and 3.5 ppm for 3-hydroxybutyrate no 2.4 ppm cross
peak was observed in the relevant samples. This may be
due to a sub-optimal mixing time in the 2D TOCSY for
observing this resonance or the typically low concentra-
tion of this metabolite. Either way the assignment can-
not be confidently confirmed.
Chemical Shift variation of small molecule metabolites
Variation in the chemical shift of peaks between
HRMAS experiments have been noted previously [21],
the most likely cause of which is that pH, salt content
and the ratio of D2O to H2O are parameters that are
not controllable in the same way as, for example, NMR
of metabolite solutions obtained from acid extractions
of tissue. If there is any variation in the flow of air to
the rotor then there is the possibility of subtle tempera-
ture variations resulting in small chemical shift varia-
tions. It is also possible that there is a systematic
variation in chemical shift between tumour types due to
consistent differences in the metabolite environments
associated with a type of tumour. In this regard, differ-
ences in the pH and chemical environments within cells
and tissues of tumours may vary the chemical shifts of
some metabolites. To ascertain the extent of this varia-
tion the chemical shift of 7 peaks that were observable
in each of 7 meningioma, 7 GBM and 7 metastases
spectra were measured with the CH3 resonance of Cr
set to 3.03 ppm as a reference. The list of the peaks,
their line width at half maximum height and standard
deviation of their chemical shift are given in Table 2.
There is a small, but non zero, variation in the 3.93
ppm Cr singlet (standard deviation 0.39 Hz) which may
be due to inaccuracy introduced by the sampling rate,
variations in the shim or even changes in relative size of
overlapping signals in the 3.9 ppm region. Similar varia-
tions in the resonance position of the selected meta-
bolites are observed. However, this variation is small
compared to the resonance peaks’ line width-at-half-
height which are 4 to 11 times greater than their posi-
tional standard deviation. The separation between the
Lac CH and CH3 signals varied by 0.69 Hz, a similar
value to the variation in the separation of the two Cr
singlets. It seems that variation in peak separation is
similar to that of peak position relative to the Cr refer-
ence and much smaller than linewidth. Individual t-tests
of the chemical shift variation of each peak in Table 2
show that there are no significant differences (p ≤ 0.05)
between tumour types. This result validates the use of a
single basis set of simulated spectra (see below) to be
used in LCModel to fit the spectra of all the different
tumour types.
Quantification of metabolites using LCModel
Individual spectra were quantified for small molecule
metabolites using a simulated basis-set of metabolite
Table 1 Chemical shift assignments of specific
metabolites
Metabolite Group Chemical Shift (ppm)
Asc CH 4.521
CH 4.019
CH2 3.752
3.729
Bet CH2 3.889
N(CH3)3 3.271
GPE CH2 4.110
CH2 3.959
3.856
CH 3.882
CH2 3.681
3.618
CH2 3.278
His CH 3.961
CH2 3.144
3.087
H-Tau CH2 3.344
CH2 2.647
This table shows the chemical shift assignments of selected metabolites that
have not been previously reported in particular types of brain tumour. The
assignments are referenced to the methyl resonance of Cr at 3.03 ppm.
Generally, assignments were made with reference to CPMG and/or TOCSY
spectra of 15 samples representing 5 different types of tumour. Assignments
in bold are taken from the literature assignments [19,33].
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spectra and LCModel. A pulse-acquire spectrum was
acquired for determining metabolite concentrations and
a second (unsuppressed) spectrum was acquired to mea-
sure the amount of H2O in the sample as a reference
signal. The mean concentration and its standard error
for metabolites are given for each tumour type in
Table 3. Examples of LCModel fits to spectra with their
residuals are given in Figure 2 for different histopatholo-
gical types of tumour. The residuals are generally small
compared to the metabolite signals. The Cramér-Rao
lower bounds are on average 34% for all metabolites,
with an average value of less than 25% for 15 of the
metabolites (Ala, Bet, Cho, Cr, Gln, Glu, Gly, GPC,
GSH, Lac, Leu, Lys, m-Ins, PCh, Tau). Overall 71% of
all metabolite fits in all of the 65 spectra have a Cra-
mér-Rao lower bound less than 25%. Lac, which is ubi-
quitous and at high concentrations, has just a 3%
Cramér-Rao lower bound on average. In practice LCMo-
del may completely miss a low level metabolite peak
thus giving it an artifactual zero concentration. Review-
ing the CPMG and TOCSY data showed that this
occurred for only 38 assignments of the 29 metabolites
evaluated over 65 spectra (i.e. 2%).
The good quality fits observed in Figure 2 were
achieved with a limited set of simulated macromolecules
given in Table 4. Each resonance in Table 4 is a Lorent-
zian singlet generated by the LCModel software to
simulate (and fit) a broad macromolecule peak. Fewer
macromolecule peaks are used in the LCModel fits pre-
sented here than in previous LCModel analyses of
ex-vivo tissue [36,37]. The macromolecule set used here
was determined as the minimal set required to achieve
flat residuals in LCModel quantifications, with no
unfitted broad resonances in any of the quantified
Figure 1 TOCSY showing GPE cross peak. A region of a TOCSY spectrum from a GBM sample showing the cross peak assignment of GPE.
Cross peaks are indicated for selected metabolites; the GPE resonance is at 3.3 ppm in the direct dimension and 4.1 ppm in the indirect
dimension.
Table 2 Chemical shift variation in 15 CPMG spectra
Resonance Ala doublet 1st
peak
Cr
CH2
singlet
Gly
singlet
Gln multiplet 3rd
peak
Lac doublet 1st
peak
PCh
singlet
Tau
triplet 2nd
peak
Chemical shift (ppm) 1.48 3.93 3.55 2.44 1.34 3.27 3.42
Standard deviation of chemical shift
in (Hz)
0.19 0.39 0.55 0.29 0.32 0.37 0.69
Average line width at half height of
peak (Hz)
2.3 3.0 2.3 3.5 2.3 3.3 2.5
This table shows the average chemical shift for 7 peaks from 15 CPMG spectra that have been referenced to the CH3 resonance of Cr. The standard deviation of
these mean chemical shifts and the average line widths of the peaks are also given.
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spectra. With only one peak simulated for lipid reso-
nances at 1.33 ppm (which vary in frequency with the
distance of the CH2 group from the terminal methyl of
the lipid) it is possible that this peak, and other lipids
and macromolecules, may not be completely fitted in
the analysis. This is compensated for by the allowed
variability in these simulated peaks (see Table 4) and by
the variability in the base line that LCModel fits to the
data. The spline base line fitted in LCModel often
includes part of the broad resonance signals (as can be
seen for the 1.3 ppm resonance in Figure 2, panels a, b,
c and e) thus making the quantification of macromole-
cules unreliable. For semi-quantitative measurements of
these peaks, more detailed simulated macromolecule
basis sets are required [36] though this is not the focus
of this paper.
Table 3 indicates those metabolites, within a particular
tumour type, that have high errors of fitting in grey. The
metabolites have a median value of the Cramér-Rao
lower-bound greater than 25%. One example, as can be
seen in Table 3, is h-Tau in metastases. Metastases have
an LCModel-calculated average concentration of 0.06
mM of h-Tau; however this is an overestimation as
there are no clearly observable h-Tau resonances in the
eight metastases samples. This highlights a natural bias
in LCModel in that metabolites are included if it results
in an improvement in the fit even if it does so without
much confidence. The uncertainty is reflected in the
Table 3 Mean metabolite concentrations by tumour group
Ast II Grade III GBM Metastases Meningioma Lymphoma
Ace
Ace
0.17 ± 0.10 0.22 ± 0.06 0.19 ± 0.04 0.15 ± 0.02 0.18 ± 0.03 0.40 ± 0.03
Ala 0.30 ± 0.13 1.06 ± 0.31 1.32 ± 0.17 0.81 ± 0.17 2.75 ± 0.46 2.59 ± 1.06
Asc 0.46 ± 0.08 0.58 ± 0.09 0.63 ± 0.10 0.60 ± 0.28 0.82 ± 0.14 2.94 ± 1.41
Asp 0.41 ± 0.13 0.37 ± 0.43 1.14 ± 0.33 0.18 ± 0.12 0.19 ± 0.06 0.73 ± 0.37
Bet 0.14 ± 0.03 0.17 ± 0.06 0.25 ± 0.04 0.10 ± 0.02 0.16 ± 0.03 0.21 ± 0.08
Cho 0.24 ± 0.05 0.26 ± 0.07 0.33 ± 0.05 0.23 ± 0.04 0.23 ± 0.04 0.34 ± 0.03
Cr 3.31 ± 0.80 3.07 ± 1.35 2.99 ± 0.39 1.24 ± 0.21 0.65 ± 0.13 2.07 ± 1.39
Glc 0.53 ± 0.22 0.19 ± 0.13 0.38 ± 0.12 0.64 ± 0.31 0.12 ± 0.07 0.55 ± 0.55
Glu 1.51 ± 0.60 3.01 ± 1.39 2.60 ± 0.33 2.28 ± 0.46 4.94 ± 0.56 4.46 ± 0.42
Gln 5.12 ± 0.56 4.63 ± 1.35 7.11 ± 0.89 2.13 ± 0.32 7.54 ± 0.92 5.44 ± 1.18
GSH 0.52 ± 0.15 0.55 ± 0.11 0.93 ± 0.11 0.96 ± 0.30 2.04 ± 0.25 1.18 ± 0.07
GPC 1.21 ± 0.14 0.77 ± 0.21 0.76 ± 0.14 0.73 ± 0.32 0.26 ± 0.07 0.42 ± 0.15
GPE 0.62 ± 0.13 1.20 ± 0.58 0.41 ± 0.10 0.69 ± 0.15 1.03 ± 0.27 0.60 ± 0.09
Gly 1.59 ± 0.54 1.52 ± 0.47 2.34 ± 0.39 0.75 ± 0.11 1.51 ± 0.22 2.18 ± 0.49
His 0.58 ± 0.13 0.65 ± 0.47 1.67 ± 0.53 0.08 ± 0.06 0.09 ± 0.04 0.82 ± 0.82
h-Tau 0.35 ± 0.12 0.58 ± 0.21 1.16 ± 0.23 0.06 ± 0.03 0.69 ± 0.20 0.36 ± 0.04
Ile 0.13 ± 0.02 0.15 ± 0.04 0.11 ± 0.02 0.25 ± 0.06 0.26 ± 0.06 0.46 ± 0.24
Lac 5.68 ± 0.66 8.91 ± 1.56 9.04 ± 1.07 5.40 ± 0.71 9.81 ± 0.89 8.83 ± 0.76
Leu 0.26 ± 0.03 0.92 ± 0.46 0.51 ± 0.09 0.56 ± 0.10 0.62 ± 0.11 1.14 ± 0.45
Lys 0.52 ± 0.20 0.61 ± 0.12 1.07 ± 0.12 1.05 ± 0.22 1.29 ± 0.17 2.31 ± 0.85
m-Ins 5.23 ± 0.92 2.02 ± 0.83 2.03 ± 0.32 0.70 ± 0.23 0.30 ± 0.08 1.36 ± 0.40
NAA 1.00 ± 0.65 1.14 ± 0.76 0.48 ± 0.15 0.29 ± 0.11 0.07 ± 0.02 1.08 ± 1.07
PCh 0.36 ± 0.12 0.45 ± 0.07 1.56 ± 0.27 0.68 ± 0.11 0.97 ± 0.12 1.10 ± 0.20
PE 0.18 ± 0.05 1.14 ± 0.76 1.97 ± 0.30 1.93 ± 0.30 1.87 ± 0.27 4.55 ± 1.72
s-Ins 0.25 ± 0.05 0.20 ± 0.10 0.20 ± 0.03 0.10 ± 0.03 0.04 ± 0.01 0.26 ± 0.04
Suc 0.11 ± 0.02 0.13 ± 0.04 0.19 ± 0.03 0.14 ± 0.03 0.28 ± 0.04 0.18 ± 0.02
Tau 1.00 ± 0.14 1.00 ± 0.23 0.85 ± 0.11 1.81 ± 0.77 1.75 ± 0.25 2.25 ± 0.74
Thr 0.31 ± 0.06 0.43 ± 0.16 0.66 ± 0.29 0.29 ± 0.07 0.44 ± 0.13 0.90 ± 0.18
Val 0.20 ± 0.04 0.31 ± 0.11 0.20 ± 0.04 0.37 ± 0.04 0.38 ± 0.05 1.02 ± 0.45
The metabolite concentrations of 65 quantified tumour samples grouped into general tumour types (Astrocytoma II, glioma grade III, GBM, metastasis and
meningioma). Metabolite concentrations are given (in mM) as group arithmetic means ± the standard error of this mean. Relatively high metabolite
concentrations that are referred to in the text as specific markers for particular tumour types are highlighted in bold type. Metabolites, for each tumour type,
with a median Cramér-Rao lower-bound of the peak fitting that is greater than 25% of the peak volume, are given in italics.
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Cramér-Rao lower bound estimates that range between
45% and 495% for h-Tau in metastases, with a median
value of 125%. An example is given in Figure 3 of a
region of a metastasis spectrum that had 0.07 mM cal-
culated h-Tau concentration, yet there is only noise
where the expected h-Tau resonances would be, as
observed in the GBM spectrum. A similar result is
found for His, which although not observable in any of
the metastasis or meningioma spectra, are given small
average concentrations as measured by LCModel of 0.08
mM and 0.09 mM respectively. The importance of using
the Cramér-Rao lower bound to assess the reliability of
a concentration measurement is highlighted by these
measurements.
Figure 2 LCModel fits of HRMAS spectra. LCModel was used to fit the simulated basis set to each HRMAS pulse acquire spectrum with water
presaturation. The six examples given here are a) astrocytoma grade II, b) lymphoma, c) an anaplastic astrocytoma, d) metastasis, e) GBM and f)
a meningioma. The red line shows the linear combination of the basis set, and the thin grey line is the base line determined by LCModel. The
residual (the fit and the base line subtracted from the raw data) is shown in a narrow box at the top of each panel.
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Changes in metabolite concentration during the experiment
T-tests were performed on 87 metabolite average con-
centration changes over 2.5 hours to see if there were
statistically significant deviations from zero, with p <
0.01. There was a significant drop in the concentration
of GPC and GSH in GBMs and a rise in Gly in all three
tumour types over three hours. These three significant
changes in GBMs over 2.5 hours are consistent with a
previous GBM study [38] that found these changes,
under similar experimental conditions (3 hr, 5000 Hz
spinning at 4°C), with Gly being the largest change in
both studies (an average increase of 0.46 mM in this
study and 0.34 mM previously [38]). A previous GBM
study [38] also reported rises in Ace, Lac, Leu and Cho
and a fall in m-Ins; these metabolites changed similarly
in this current study though not significantly. The
increase in Cr, Glu and Ala previously observed [38]
were not observed in this current study, but instead a
non-significant decrease occurred. The reasons for the
greater number of significant changes in the previous
study may be the slightly longer time course (3 hours as
opposed to ~2.5 hr in our study). Changes over 28 min-
utes and 2.5 hours are shown for Gly, GSH and GPC in
Figure 4. The graphs suggest that for the three different
tumour types there is a fall in GPC and GSH and a rise
in Gly. These changes are of the order of less than 0.5
mM over three hours so are not significant in the case
of simply acquiring the spectra for measuring metabolite
concentration, which can be performed with 15 minutes
of data acquisition and within half an hour from the
start of sample spinning at 4°C. One possible exception
is Gly that has a significant (p = 0.007) rise in concen-
tration over 28 minutes in GBMs. This suggests that
Gly is at a higher ‘NMR visible’ concentration in an
Table 4 Macromolecule peaks simulated in LCModel
Molecular group of the
resonance
Chemical shift
(ppm)
Line width
(Hz)
Lipid -CH3 0.969 ± 0.05 0.1 ± 0.09
Lipid -CH2-...-CH2-CH2-CH3 1.333 ± 0.05 0.1 ± 0.09
Lipid -CH2-CH2-COOH 1.609 ± 0.01 0.04 ± 0.02
Lipid -CH2-CH = 2.056 ± 0.01 0.04 ± 0.02
Lipid -CH2-COOH 2.277 ± 0.01 0.04 ± 0.02
Lipid = CH-CH2-CH = 2.829 ± 0.01 0.04 ± 0.02
Lipid = CH-CH2-CH = 2.858 ± 0.01 0.04 ± 0.02
MM (protein) 3.285 ± 0.01 0.04 ± 0.02
The simulation parameters of broad macromolecule resonances for LCModel
that were included in the fit of each spectral quantification. The chemical shift
and line width with their allowed range of variability (±) are given alongside
the molecular group that each broad singlet is simulating (highlighted in
bold). MM (protein) refers to a variety of protein signals that produce a broad
resonance in this region.
3.4 3.2 3.0 2.8 2.6 2.4
Chemical shift (ppm)
 GBM
 Metastasis
Figure 3 Absence of h-Tau in metastases. This figure shows two pulse-acquire specta. The spectrum of a GBM shows the position of the two
triplet resonances of h-Tau. The metastasis shows noise in these same regions of the spectrum despite LCModel fitting a small amount of h-Tau
when quantifying this spectrum.
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HRMAS sample than in the in vivo tumour. The source
of this extra Gly could be metabolic processes or the
release of a ‘bound’ species due to sample damage that
occurs in the HRMAS experiment. Gly could be released
by the action of proteolytic enzymes on cellular proteins
in the sample. In contrast, most metabolites have not
changed significantly in metastases, meningioma and
GBM though each has slight losses of GSH and GPC. It
is possible that the GPC and GSH concentrations given
here are lower when compared to tumour concentra-
tions in vivo though any changes in the time taken to
acquire quantitative 1D spectra will be small. GSH and
GPC concentration changes are similar for three differ-
ent histopathological types of tumour, therefore any
comparisons in relative concentration of these metabo-
lites between tumour types (see below) should still be
valid.
Our current measurements can indicate the size of
metabolite changes observed during conditions of an
HRMAS experiment but not of those that occur prior to
that point. Sample ischaemia is known to produce rapid
increases in Ala and Lac concentrations (reviewed in
[38]) such that these metabolites (along with Glc) are
significantly different between in-vivo and ex-vivo mea-
surement [14]. These metabolite concentrations will be
artificially high in ex-vivo studies, but that does not
necessarily suggest that the results presented here for
these metabolites are not without significance [13]. Ala
has been found to be significantly higher in meningio-
mas compared to other tumour types in this ex-vivo
data (see the section on “Statistical analysis of individual
metabolite differences between tumour types”) which is
in good agreement with its observation in significant
concentrations in meningiomas in vivo [39,40]. Rapid
increases in Ala is also a feature of the early stages of
epileptic seizures prior to the formation of neuronal
lesions [16].
Histopathology of post HRMAS samples
After the HRMAS protocol 52 samples were fixed in
formalin, stained with hematoxylin and eosin and sent
for histopathological review for comparison with the
initial histological diagnosis. A single GBM sample had
deteriorated so much during the HRMAS that there was
no sizeable portion of intact tissue left to fix. Other
samples fractured into multiple pieces on removal from
the rotor but were still fixed and stained successfully
(see the insert panel of Figure 5 for an example).
Table 5 summarises the results of post HRMAS histo-
pathology in which the histopathologist was asked to
assess the tissue for damage, necrosis and to make a
most likely diagnoses of these 52 intact samples. The
same tumour type (glioma, metastases, meningioma or
lymphoma) was identified for 38 samples (73%) in post
HRMAS histopathology compared to the original diag-
nosis. Of these agreements in tumour type, 10 glioma
samples had different grade of malignancy compared to
the original diagnosis. Table 5 shows GBM grade of
HRMAS sample was lower than the grade determined
from the full clinical diagnosis in all but 2 cases, with
grade II (and in one case grade III) astrocytoma being
suggested instead. An example of a GBM sample graded
as astrocytoma II post HRMAS is given in Figure 5
showing a lack of malignant features that would confirm
a high grade diagnosis. A previous study [5] suggested
that post-HRMAS, GBM samples sometimes lack char-
acteristic malignant and necrotic histopathological fea-
tures and that regions of necrosis are compressed by
sample spinning. The underestimation of glioma grade
may be the result of avoiding necrotic regions when pre-
paring the sample or changes due to sample spinning.
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Figure 4 Metabolite concentration changes over time under HRMAS experimental conditions. These three line graphs plot the change in
mean metabolite concentration with time over the course of 28 minutes and 2 hours 33 minutes. Error bars show the standard error of the
change in the mean. Changes are shown for Gly, GSH and GPC which have significant changes over 2 hours 33 minutes and the different
tumour types in each plot are indicated by the colour key.
Wright et al. Molecular Cancer 2010, 9:66
http://www.molecular-cancer.com/content/9/1/66
Page 8 of 18
Six samples were too necrotic or damaged for post-
HRMAS histopathology and there were five misdiag-
noses (four meningiomas and one metastasis) which all
had very small and/or highly damaged samples that
severely compromised the ability to make a robust his-
topathological diagnosis. There were also three samples
(two astrocytomas and one metastasis) where brain tis-
sue but no tumour cells were observed. These samples
had elevated levels of NAA which is a marker for nor-
mal brain (glial and neuronal cells), with 2 to 4 mM in
the two glioma samples but only 0.8 mM in the metas-
tasis; these concentrations are far lower than would be
expected for a sample purely from normal brain [19].
The presence of normal brain cells highlights that in
resected-diffuse astrocytoma or metastasis there is often
some normal tissue excised with the tumour which may
be sampled in the HRMAS experiment. This tissue may
be structurally more robust and so dominate the post
HRMAS sample for histopathological analysis.
Discrepancies in tumour grade and undiagnosable
samples are the result of damage to the sample in a
minority of post-HRMAS histopathological reviews.
Damage to the samples can be greatly reduced with
shorter experiment times than are used here, which
include the 2D TOCSY experiments used for detailed
resonance assignment. With shorter protocols there
would be fewer samples lost due to mechanical damage
from spinning. Slower spinning speeds may also reduce
sample damage and could be employed as long as spin-
ning side bands remain outside the metabolite regions
Figure 5 Post-HRMAS histopathology of a GBM sample. Hematoxylin and eosin stained slide of a fixed, post-HRMAS sample from a GBM
patient. The insert shows the entire cut section on the slide with the characteristic fragmenting of the sample that occurs during the HRMAS
experiment. The main picture shows a high density of disorganised nuclei indicative of tumour but not the features of high grade malignancy
that would confirm a diagnosis of GBM.
Table 5 Post-HRMAS histopathological review of samples
Clinical diagnosis Number reviewed Matching histology Normal tissue Necrotic or damaged Mismatched histology
Ast. II 4 3 1 0
Grade III 5 3 1 1 1 Ast. II
GBM 12 2 0 1 8 Ast. II
1 Grade III
Metastasis 8 6 1 0 1 Meningioma
Meng. 20 11 0 4 4 Glioma
1 Ependymoma
Lymphoma 3 3 0 0
This table summarises the histopathological diagnoses of the tumour samples that were fixed and stained. Tumours are grouped as ast. II (astrocytoma II), grade
III (the grade III gliomas), meng. (meningioma), metastasis and lymphoma. The table counts those that had matching diagnoses clinically and in post-HRMAS
review and gives details where there was a mismatch. Those that were extensively normal appearing brain tissue and those too necrotic or damaged for
histopathological verification are counted for each tumour group.
Wright et al. Molecular Cancer 2010, 9:66
http://www.molecular-cancer.com/content/9/1/66
Page 9 of 18
of the spectra. Even in the examples presented here,
with 2.5 hours spinning at 5 kHz, a majority of samples
still had large numbers of observable tumour cells and a
correct diagnosis in post-HRMAS histopathology. How-
ever, we do not recommend that such long HRMAS
times are used if correlation to detailed histopathological
analysis post-HRMAS is a major aim.
Statistical Analysis and determination of tumour
biomarkers
Statistical analysis of individual metabolite differences
between tumour types
Significant differences in metabolite concentrations
between histopathological types were found for Ala,
Asp, Cr, Glu, Gln, GSH, GPC, Gly, His, h-Tau, Ile, Lac,
Lys, m-Ins, NAA, PCh, PE, s-Ins, Tau, Val using a Krus-
kal-Wallis test of the concentration data. Individual
Mann-Whitney-U tests were performed for each of
these metabolites to compare their concentrations pair-
wise between histopathological tumour types (sum-
marised in Table 6). These results show a variety of dif-
ferences at a high level of significance (p < 0.01)
between glioma, lymphomas, metastases and meningio-
mas. These metabolites have potential as biomarkers for
tumour differentiation in these binary comparisons. Sig-
nificant differences were not observed between the
groups with five or less samples (lymphoma, astrocy-
toma II and grade III glioma) as there are too few repe-
titions to give significant results at p < 0.01. There are
also no significant differences between grade III glioma
and GBM which may be the result of, the heterogeneity
of the grade III glioma group that contains astrocytomas
and oligoastrocytomas, the small sample size of grade III
glioma group, or the heterogeneity of grade IV gliomas.
There is similar difficulty in separating grade III and IV
gliomas in vivo by MRS. Meningiomas show the largest
number of metabolite differences when compared to the
other tumour types. In particular meningiomas have sig-
nificantly lower Cr concentrations than lymphomas,
grade II astrocytomas, GBMs and metastases and higher
Ala and Glu than these groups. In in-vivo MRS at 1.5T,
Ala and the broad peak of Glu and Gln (referred to as
Glx and observable at 2.4 ppm) have been previously
proposed as markers of meningiomas [39,40]. The data
presented here suggests that Gln in meningiomas is at a
similar concentration to GBM (see Table 3) but Glu is
larger in meningiomas which may account for the
increase in the combined Glx signal. GSH has been pre-
viously suggested as an in-vivo marker of meningiomas
when compared to normal brain and gliomas [41] and is
significantly higher compared to all three glioma grades
in this current data.
An important distinction clinically is between metasta-
sis and glioblastomas [42], tumours which can have a
similar radiological appearance [3]. The Mann-Whitney-
U test suggests significant positive biomarkers for GBM
would be Cr, Gly, Gln and h-Tau. Conversely there are
no potential positive biomarkers for metastasis in this
comparison.
There are significant differences in the levels of two
metabolites between low grade gliomas and GBMs.
Astrocytoma IIs have higher m-Ins and GBMs have
Table 6 Significant differences in metabolite concentration in binary comparisons between tumour type
Tumour type 1 Tumour type 2 Significantly higher concentration in tumour type 1 Significantly higher concentration in tumour type 2
lymphoma Astrocytoma II
lymphoma Astrocytoma III
lymphoma GBM Tau*
lymphoma Metastasis h-Tau
lymphoma Meningioma Cr* Ala**, Glu*, Gln**, Lac*
Astrocytoma II Astrocytoma III
Astrocytoma II GBM m-Ins* Ala
Astrocytoma II Metastasis Gln*, m-Ins*, PE*
Astrocytoma II Meningioma Cr**, GPC**, His**, m-Ins**, s-Ins** Ala**, Glu*, GSH**, PE
Astrocytoma III GBM
Astrocytoma III Metastasis h-Tau*
Astrocytoma III Meningioma GPC*, m-Ins* GSH*, Lys
GBM Metastasis Cr, Gln*, Gly*, h-Tau*
GBM Meningioma Asp, Cr**, GPC*, His*, m-Ins**, NAA*, s-Ins** Ala, Glu*, GSH**, Ile*, Tau, Val*
Metastasis Meningioma Cr* Ala**, Glu*, Gln**, Lac*
A non-parametric Mann-Whitney-U test was used to compare for significant differences in metabolite concentrations between two general tumour types. This
was repeated for all binary comparisons of the tumour groups with a significance level of p < 0.01. Significantly higher tumours are listed by abbreviation. Higher
significance levels are indicated with asterisks * = p ≤ 0.005, ** = p ≤ 0.001.
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higher Ala. These are two potential positive biomarkers
of high and low grade glioma in agreement with other
ex-vivo HRMAS work [6]. Furthermore, high m-Ins is a
feature of in-vivo short echo time spectra of astrocyto-
mas but not of GBMs [1,2,43]. Although studies by
Kinoshita et al. [44,45] of acid extracts of brain tumour
samples showed an increase in m-Ins and Ala with
tumour grade, the discrepancy may be the result of
using an acid extraction method as compared to whole
tissue.
Multivariate analysis of metabolite differences between
tumour types
A multi-variate analysis of variance (MANOVA) has
been performed on the tumour metabolite concentration
data. This statistical test assumes a normal distribution
of the data, which is generally not the case for metabo-
lite concentrations. Despite this, the analysis can be
used as a supervised clustering technique, also called
discriminate analysis, by plotting canonical variables as
in Figure 6. Canonical variables are linear combinations
of the different amounts of each metabolite in each
sample. The concentrations of metabolites are normal-
ised by dividing each metabolite concentration by its
mean over all 65 samples. The first canonical variate is
calculated as the linear combination of the normalised
metabolite-concentrations that produces the most
significant analysis of variance (ANOVA) between the
histopathological groupings. The variables of this first
canonical vector are plotted on the x axis in Figure 6a.
The second canonical variate (y axis) is the second most
significant ANOVA in the data that is orthogonal to the
first canonical variate. As can be seen from Figure 6a,
the majority of the meningioma samples are separated
from the other tumours types by having low values of
canonical-variate 1. The relative contributions of the
normalised metabolite concentrations to this variate are
given in Figure 6b. Negative values of high magnitude
that contribute to this variate include Glu and Ala.
These have already been found to be significantly high
in meningiomas compared to other tumour types. The
other high contributing metabolites are Ile and Tau. Bar
charts of these metabolites are given in Figure 7a. From
the bar chart it can be seen that Ile and Tau may pro-
vide positive markers for meningiomas when compared
to gliomas. Tau is also significantly higher in meningio-
mas than in GBMs (see Table 6). However Ile and Tau
would not separate meningiomas from metastases and
lymphomas, which have similar concentrations of these
metabolites (Figure 7a).
Canonical variate 2 clearly separates the three lympho-
mas from the grouping of all the other tumour types,
suggesting that there are characteristic metabolites that
Figure 6 MANOVA analysis of normalised metabolite concentrations. a) Scatter plot of the first two canonical variables of the MANOVA
analysis of the 6 different tumour types. Each individual sample is plotted with a colour particular to its tumour type as indicated in the key. b)
The relative contributions of the normalised amount of metabolite that form Canonical Variate One are expressed as a bar chart. The most
significant negative contributions in the linear combination are labelled with the metabolite abbreviation. c) The bar chart showing the
combination that forms Canonical Variate Two. Here the largest positive contributing metabolites are labelled.
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Figure 7 Bar charts of key metabolites in MANOVA. a) The mean metabolite concentrations (in mM) for four metabolites in each of the six
groups of tumour indicated by the key. These metabolites contribute the most to Canonical variate 1 in Figure 6b. Error bars are given as the
standard error of the mean. These are the four metabolites that were found to be important in the MANOVA separation of meningiomas from
other tumour types. Due to the small number of samples the error in the estimation of Glu in Grade III gliomas makes any comparison
statistically insignificant. b)The mean metabolite concentrations (in mM) for six metabolites in each of the six groups of tumour indicated by the
key. These metabolites contribute the most to Canonical variate 1 in Figure 6c. Error bars are given as the standard error of the mean. These are
the four metabolites that were found to be important in the MANOVA separation of lymphomas from other tumour types.
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can be used for lymphoma classification. MRS biomar-
kers for lymphoma may prove useful as the radiological
appearance of these tumours can sometimes resemble
that of glioblastoma [46,47]. Strong positive contribu-
tions to the linear combination of canonical variate 2
are labelled in Figure 6c. Six metabolites (Asc, Gln,
NAA, PE, s-Ins, Val) showed these strong positive con-
tributions, of which, three: Asc, PE and Val show parti-
cularly high mean concentrations compared to other
tumour types (see Figure 7b). These three metabolites
may prove useful biomarkers of lymphomas in compari-
son to other common types of brain tumour. None of
these three metabolites were significantly different
between lymphoma and other tumour types in the
Mann Whitney U analysis (see Table 6) though this is
unsurprising as there were only three lymphoma sam-
ples in the data set. Asc is a novel assignment in this
study and was found in most of the tumour samples
with the highest average concentration in lymphomas. It
is unclear as to the significance of its presence though.
Asc is thought to provide an important anti-oxidant
function in normal brain and Asc radicals are cytotoxic
to glioblastoma cell lines [48]. Asc has been observed in
normal brain with in-vivo MRS using the MEGA-PRESS
spectral editing techniques [49]. Consideration of the
known (prescribed) medication of patients at the time of
surgical resection did not suggest any possible extrinsic
sources of Asc.
Other differences in metabolite concentration between
tumour type
There are particular metabolites only observable in the
spectra of some tumour types that could provide useful
positive biomarker for tumour diagnosis. H-Tau is sig-
nificantly higher in lymphomas, GBMs and astrocytoma
grade III tumours than metastases. The absence of
NMR-observable h-Tau from metastasis could make it a
useful positive biomarker for GBM in a binary GBM-
metastasis comparison. His could, similarly, be a useful
positive biomarker for gliomas when compared to
metastases. However, there is a complete absence of
observable His in 10 of the 24 GBM samples, which
may reflect the low metabolite concentration of these
more necrotic GBMs, which have higher lipid signals as
shown in Figure 8a. His has resonances in a spectral
region (3.2 - 3.1 ppm) that do not overlap with other
strong signals though other studies have reported tyro-
sine and phenylalanine [7] resonances in glioblastomas
in this region. His is a possible target for a selective
pulse sequence in in-vivo spectroscopy at field strengths
higher than 3 Tesla but the low concentration, particu-
larly in necrotic tissue, may make it undetectable in
many in-vivo GBMs.
M-ins and Ala are significantly different between the
low grade glioma and GBM in this study. Comparing
average metabolite concentrations between the groups
can give some insight into other potential markers of
tumour grade. It has been previously reported that
Grade II astrocytomas have higher GPC and lower PCh
than grades II and IV [50]. The results presented here
(see Figure 8b) suggest a similar trend of increasing PCh
and decreasing GPC with grade, which was also
observed previously in high resolution in vitro NMR of
pechloric acid extractions of gliomas [51]. The relative
amounts of GPC and PCh could prove useful markers
of tumour grade in in-vivo MRS in the future if higher
fields are employed to resolve their resonances.
Conclusions
Ex-vivo HRMAS spectroscopy can reveal the NMR visi-
ble small molecule metabolites from adult brain
tumours. Careful assignment of these metabolites has
allowed novel assignments not previously reported for
particular brain tumour types. These include the identi-
fication of Asc and GPE in various adult brain tumours,
h-Tau in gliomas, lymphomas and meningiomas, and
Bet in gliomas. The quantification of brain tumour
metabolites has allowed the identification of significant
differences in the amounts of particular metabolites, and
these could provide novel biomarkers of brain tumour
histopathological type in vivo. There are statistically sig-
nificant higher concentrations of Cr, Gln and h-Tau in
GBMs compared to metastases that may prove useful
positive biomarkers for high-grade glioma versus metas-
tasis, as may His, which is not observable in metastases.
A MANOVA analysis revealed that lymphomas have a
distinctive metabolic profile. Average concentrations for
Asc, PE and Val are high for lymphomas though the
low sample number (n = 3) requires further samples to
be analysed to confirm these findings.
Concentration measurements have also identified var-
ious positive markers for different brain tumour types
that correspond to previous in-vivo and ex-vivo studies
[2,6,39-41,43,50]. In this regard meningiomas have
significantly high Ala and low Cr compared to other
metabolites. Glu has been shown to be the component
of in-vivo “Glx” peaks that are high in meningiomas.
There is also evidence to support m-Ins, GPC, Ala and
PCh as biomarkers for discriminating low and high
grade glioma.
Concentration measurement by HRMAS spectroscopy
requires careful experimental design as Gly in glioblasto-
mas increases significantly in the time period required
to acquire quantitative 1D spectra. Furthermore, long
HRMAS protocols (2.5 hr) at high spinning speeds
(5 kHz) can cause tissue damage that compromises post
HRMAS analysis in some samples, and particularly
those that have necrotic regions. HRMAS has been used
to confirm potential biomarkers for brain tumour
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Figure 8 Other metabolite differences between tumour types. This figure shows two pulse acquire spectra of GBM samples. The spectrum
shown in black has clear His signals in the 3.2 - 3.1 ppm region. The spectrum in red has only noise in this region and generally lower small
molecule metabolite signals but much higher lipid signals as indicated in the 1.3 ppm and 0.9 ppm regions. b) This bar chart plots the mean
concentration of GPC and PCh, with error bars of the standard error of the mean, for three of the tumour groups: astrocytoma grade II, grade III
gliomas and the (grade IV) GBMs.
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prognosis and diagnosis currently identified from in-
vivo, in-vitro and ex-vivo techniques. The extra resolu-
tion and analysis of unprocessed tissue that HRMAS
provides has allowed novel identification of further bio-
markers, with potential use in clinical practice.
Methods
Sample collection
Samples were collected from 65 brain tumour patients
at St George’s, University of London. Informed consent
was provided by each patient and the study was
approved by the local ethics committee (Local Ethics
Reference: 06/Q0803/184). Surgically resected brain
tumours had samples snap-frozen in liquid nitrogen for
subsequent HRMAS and other samples sent for routine
histopathology. Consensus diagnosis was made for each
of the brain tumour patients, by clinicians at St Georges
Hospital, according to local practice that included histo-
pathological analysis of multiple samples other than
those used in this HRMAS study. Included in this study
were 4 diffuse astrocytomas, a gemistocytic astrocytoma,
3 anaplastic astrocytomas, 2 anaplastic oligoastrocyto-
mas, 24 GBMs, 3 lymphomas, 8 metastases and 20
meningiomas. The frozen samples were stored at -80°C
until used for HRMAS. Due to the small sample num-
bers available the analysis in this paper has been limited
to broad groups of related histopatology: astrocytoma
grade II, grade III gliomas (including the astrocytomas
and oligoastrocytomas), GBM, the meningiomas and a
group of the lymphomas.
Sample preparation and HRMAS
Samples were dissected on dry ice to give a 5 - 25 mg
fraction that was inserted into a chilled 50 μl HRMAS
rotor insert containing 10 μl of frozen 10 mM Sodium
Formate (as a chemical shift reference) in D2O. The
insert was filled with more D2O, capped, and quickly
transferred into an HRMAS rotor (Bruker Biospin, Cov-
entry, UK) that had been cooled on ice. The rotor was
transferred to the NMR spectrometer that had been
pre-cooled to a sample temperature of 4°C. HRMAS
experiments were performed using a Bruker Avance 600
MHz NMR spectrometer fitted with a 4 mm quadruple-
tuned HRMAS probe (1H, 2H, 13C, 31P). The sample
was maintained at a constant internal temperature of 4°
C and a spin rate of 5000 Hz. The sample was left at
these conditions for 15 minutes prior to acquisition to
allow temperature equilibration. A standard protocol for
the experiments was set up:
1) Presaturation pulse acquire with a repetition time
(TR) of 3.14 s and a total time for acquisition
(TTA) of 3 min 48 s.
2) Presaturation pulse acquire TR 9.14 s, TTA 1 min
50 s
3) Pulse acquire TR 3.14 s, TTA 10 min 23 s
4) CPMG TTA 11 min 46 s
5) Presaturation pulse acquire TR 3.14 s, TTA 3 min
48 s
6) TOCSY, TTA 2 hrs 1 min
7) Presaturation pulse acquire TR 3.14 s, TTA 3 min
48 s
The full acquisition protocol was acquired for 53 of
the 65 samples and acquisitions 1 to 4 were acquired
for the remaining 12. All the one dimensional sequences
were acquired with a band width of 7184 Hz and 8192
complex points. Sequence 3 had a water suppression of
60dB, 64 scans. Sequence 2 was identical to 3 except
that no water suppression pulse was applied to enable
tumour water content to be used as a reference signal
for metabolite quantification and there were only
8 scans. Sequences 1, 5 and 7 were identical with
64 scans, sequence 5 occurred 28 minutes after the
initial acquisition and sequence 7 was 2 hours and 33
minutes later. The CPMG sequence was acquired with a
50 ms echo time with inter-echo spacing of 0.4 ms, 128
scans and a repetition time of 6.14 s. TOCSY spectra
were acquired with water presaturation, 16 scans of
7184 Hz bandwidth and a 70 ms DIPSI-2 isotropic mix-
ing sequence in the direct dimension with 256 incre-
ments in the indirect dimension. The entire acquisition
protocol took 2 hrs 37 minutes to perform, after which
the rotor was immediately removed from the spectro-
meter placed onto ice and the tissue fragment taken out
and placed into a 4% formaldehyde solution.
Post-HRMAS histopathology
Once fixed, tissue fragments were put into paraffin
blocks for sectioning and then stained with hematoxylin
and eosin for histopathological analysis. Histopathologi-
cal slide preparation and photography was provided by
the CRUK Cambridge Research Institue (CRI, Robinson
Way, Cambridge, UK). Post HRMAS histopathological
analysis was provided by Dr. Andrew Dean (Aden-
brookes Hospital, Cambridge UK). Two non-adjacent
slices from each biopsy sample were assessed for per-
centage necrosis, sample damage, and were given a
most-likely histopathological diagnosis of tumour type
where possible. Histopathological analysis was com-
pleted for 52 samples.
Processing of HRMAS data
For assignment, all spectra were Fourier transformed using
TOPSPIN (Bruker Biospin), referenced to the Sodium For-
mate singlet at 8.45 ppm. The chemical shift and line
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widths at half height for the singlets of Cr, Gly, PCh, were
measured using TOPSPIN by fitting lorentzian peak
shapes to the CPMG spectra. Line-widths were similarly
found for the higher field peaks of the doublets of Lac and
Ala and the chemical shifts of these resonances (plus the
Lac quartet) were also determined. The chemical shifts are
reported in Table 2 relative to Cr at 3.03 ppm.
A GBM and a metastasis spectrum contained very
high level signals from mannitol and so were not
included in the set of 65 analysed samples.
Simulated basis set of small molecule metabolites
A subset of 15 brain tumour samples of varying histo-
pathological type (3 lymphoma, 3 astrocytoma II, 3 GBM,
3 metastases and 3 meningiomas) were analysed for the
chemical shift of assignable resonances in their CPMG
spectra. Where there were more than 3 spectra in a
tumour type then representative spectra had to be
selected (particularly for GBM, meningioma and metas-
tases). The selection criteria were to choose samples with
the most resonances, clearly resolvable above the noise,
in both the CPMG and TOCSY spectra. An average che-
mical shift was calculated from each peak in as many of
the CPMG spectra in which the resonance was present
and resolved. Multiplets without clearly resolved peaks in
one dimensional spectra were assigned chemical shift
values from average peak positions in TOCSY spectra.
The multiplets assigned in this way were 3.79 ppm of
Ala, 3.30 ppm and 4.13 ppm of GPE, 3.84 ppm and 2.22
ppm of GSH, 1.43 ppm and 4.37 ppm of Thr and 3.46
ppm and 3.68 ppm of Glu. Further multiplet resonances
were undetectable above the noise in any spectrum and
were therefore assigned, relative to known shifts, from
H2O solution values in Govindaraju et al. [19] or the
Human Metabolome Project [33]. Some of these ‘litera-
ture assignments’ are indicated in Table 1 by the grey
colour of the chemical shift. Basis sets were simulated
using TARQUIN [11,21] with scalar coupling constants
taken from Govindaraju et al. [19]. Additional scalar cou-
pling information was obtained from the Human Meta-
bolome Project database [33] or, in the case of Asc, were
estimated from a 1D spectra of a pure solution. The
TARQUIN software was used with MATLAB [52] to
simulate the metabolite basis sets that most accurately
reproduced the average peak positions from the 15 sam-
ples. A singlet was also simulated for quantification of
the water resonance in acquisition 2 of the NMR experi-
ments. Individual simulated spectra were combined into
basis sets in LCModel for quantification of spectra.
Simulation of macromolecule signals
Assignments of broad signals from lipid and protein
macromolecules were also made from the subset of 15
spectra. These signals were fit with a small set of broad
Lorentzian singlets, generated by LCModel for each ana-
lysis, with varying chemical shift and line width as
detailed in Table 4.
Quantification of spectra
The raw time domain data from the pulse acquire
experiment of sequence 3 in the acquisition protocol
was loaded into LCModel and quantified with the simu-
lated basis set and the simulated macromolecule signals.
For metabolite concentrations the unsuppressed water
signal (from sequence 2 of the acquisition protocol) was
also quantified using the TARQUIN-simulated singlet in
a basis-set. Metabolite concentrations were calculated
according to the formula:
Metabolite concentration metabolite amount water amount  ( ) 55M water conc.
which gives the quantification as a concentration of
the metabolite (in mM) as if it were dissolved in the tis-
sue water in the sample rather than in the complete tis-
sue volume. It is a potential concern that the D2O
added to the rotor exchanges with water prior to and
during sample collection thus artificially diluting the
metabolites. This was assessed by preparing a sample
containing just the 10 mM formate solution in D2O,
waiting the same amount of time until acquisition as for
a tumour sample then performing a water-unsuppressed
pulse acquire measurement. The relative concentration
of H2O in the D2O can then be calculated revealing that
there is a negligible amount of H2O in the 10 - 20 μl of
added D2O compared to the water content of 5 - 25 mg
of tissue.
Statistical analyses
The average chemical shift of 7 different metabolite
peaks was compared for 3 groups of tumour type,
meningioma, GBM and metastases, using individual
t-tests at a significance level of p ≤ 0.05 to reject the
null hypothesis of no difference between tumour types.
A Kruskall-Wallis test was performed to find metabo-
lite concentrations that showed significant differences
between groups of different tumour type (grade II
astrocytoma, grade III glioma, GBM, metastases and
meningioma; p ≤ 0.05). Mann-Whitney-U tests were
performed to determine the significant metabolite
concentration differences with binary combinations of
the different tumour types and with a conservative
significance level of p < 0.01. Changes in metabolite
concentrations during the HRMAS experiment were
determined from acquisitions 1, 5 and 7 in the spec-
troscopy protocol given above. These three identical
pulse acquire spectra were collected at the start of the
protocol then 28 minutes later and 2 hrs 33 minutes
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after the start. Changes in concentration were followed
for 8 samples in each of three tumour types (menion-
gioma, GBM and metastasis) by LCModel fitting of the
spectra. This allowed any metabolite concentration
changes to be measured over these time periods. Meta-
bolite concentrations were excluded from the analysis
if they were incorrectly missed out from the LCModel
fits; therefore there were a maximum (but not necessa-
rily) 8 concentration changes measured for each of the
three tumour types. In this regard, there were, on aver-
age, 5.6 repeat measurements for each of the 29 meta-
bolites in each tumour type. Concentration changes
were calculated for the ~2.5 hour period by subtracting
the quantified amounts of acquisition 1 from acquisi-
tion 7. The concentration change was calculated by
assuming the initial quantity was that measured from
acquisition 3 (as described in the section “quantifica-
tion of spectra”). Mean changes in metabolite concen-
tration changes over ~2.5 hours for each tumour type
were calculated and t-tested against a null hypothesis
of no change in metabolite concentration. Similar cal-
culations were made for metabolite changes over the
28 minute period between acquisition 1 and 5. The
Kruskall Wallis, Mann Whitney U, and t-tests were
performed using SPSS [53].
MANOVA was performed using the statistics toolbox
of MATLAB [52]. Metabolite concentrations were nor-
malised by dividing each value by their mean value over
all 65 spectra. The MANOVA was performed as a dis-
criminate function analysis to generate canonical vari-
ables which had the maximal separation of the means of
the 6 different tumour types. Each canonical variable is
a linear combination of the normalised concentration
values of the 29 different metabolites.
Abbreviations used
3T: 3 Tesla; Ace: Acetate; Ala: Alanine; ANOVA: Analy-
sis of Variance; Asc: Ascorbate; Asp: Aspartate; Bet:
Betaine; Cho: Choline; CPMG: Carr-Purcell-Meiboom-
Gill; Cr: Creatine; GBM: Glioblastoma Multiforme; Glc:
Glucose; Glu: Glutamate; Gln: Glutamine; Glx: Gluta-
mate plus Glutamine; GSH: Glutathione; GPC: Glycero-
phospho-choline; GPE: Glycerophospho-ethanolamine;
Gly: Glycine; His: Histidine; hr: hour; HRMAS: High
Resolution Magic Angle Spinning; H-Tau: Hypo-taurine;
Ile: Isoleucine; Lac: Lactate; Leu: Leucine; Lys: Lysine;
MANOVA: Multi-variate Analysis of Variance; min: min-
ute; M-Ins: Myo-Inositol; MRS: Magnetic Resonance
Spectroscopy; ms: milli-second; NAA: N-acetyl-aspartate;
NMR: Nuclear Magnetic Resonance; PCh: Phosphocho-
line; PE: Phospho-ethanolamine; ppm: part-per-million;
S-Ins: Scyllo-inositol; Suc: Succinate; Tau: Taurine; Thr:
Threonine; TR: Repetition time; TTA: Total Time of
Acquisition; TOCSY: Total Correlation Spectroscopy;
Val: Valine.
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